Progenics Pharmaceuticals Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Progenics (PGNX) PT Lifted at Needham & Company on Relistor Tailwinds, Expanded Imaging Pipeline
August 6, 2015 1:20 PM EDTNeedham & Company analyst Chad Messer raised sales estimates and his price target on Buy-rated Progenics Pharmaceuticals (NASDAQ: PGNX) to $11.00 (from $9.00) citing Relistor tailwinds and expanded imaging pipeline.
Messer commented, "We are increasing our sales estimates for Relistor (and thus our PGNX price... More
Progenics Pharma (PGNX) Misses Q2 EPS by 3c
August 6, 2015 9:07 AM EDTProgenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.63 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
... More